Millennium Management’s ImmunityBio IBRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $10.9M | Buy |
1,420,244
+1,301,816
| +1,099% | +$8.91M | ﹤0.01% | 2094 |
|
|
2025
Q4 | $234K | Buy |
118,428
+70,132
| +145% | +$159K | ﹤0.01% | 5393 |
|
|
2025
Q3 | $119K | Sell |
48,296
-3,195,410
| -99% | -$8.23M | ﹤0.01% | 5668 |
|
|
2025
Q2 | $8.56M | Buy |
3,243,706
+2,813,953
| +655% | +$7.57M | ﹤0.01% | 2434 |
|
|
2025
Q1 | $1.29M | Buy |
429,753
+195,675
| +84% | +$593K | ﹤0.01% | 4155 |
|
|
2024
Q4 | $599K | Sell |
234,078
-882,687
| -79% | -$3.68M | ﹤0.01% | 4602 |
|
|
2024
Q3 | $4.15M | Buy |
1,116,765
+1,023,174
| +1,093% | +$4.73M | ﹤0.01% | 3007 |
|
|
2024
Q2 | $591K | Buy |
93,591
+39,242
| +72% | +$259K | ﹤0.01% | 4486 |
|
|
2024
Q1 | $292K | Sell |
54,349
-5,959
| -10% | -$27K | ﹤0.01% | 5159 |
|
|
2023
Q4 | $303K | Buy |
60,308
+16,147
| +37% | +$50.7K | ﹤0.01% | 4955 |
|
|
2023
Q3 | $74.6K | Buy |
+44,161
| New | +$88.7K | ﹤0.01% | 5406 |
|
|
2023
Q2 | – | Sell |
-520,831
| Closed | -$948K | – | 6364 |
|
|
2023
Q1 | $948K | Buy |
+520,831
| New | +$1.62M | ﹤0.01% | 4140 |
|
|
2022
Q4 | – | Sell |
-399,271
| Closed | -$1.98M | – | 6760 |
|
|
2022
Q3 | $1.98M | Sell |
399,271
-780,514
| -66% | -$3.56M | ﹤0.01% | 3746 |
|
|
2022
Q2 | $4.39M | Buy |
1,179,785
+569,696
| +93% | +$2.29M | ﹤0.01% | 2941 |
|
|
2022
Q1 | $3.42M | Buy |
610,089
+332,786
| +120% | +$2.04M | ﹤0.01% | 3361 |
|
|
2021
Q4 | $1.69M | Buy |
277,303
+211,970
| +324% | +$1.59M | ﹤0.01% | 3929 |
|
|
2021
Q3 | $636K | Buy |
65,333
+1,686
| +3% | +$18.6K | ﹤0.01% | 5122 |
|
|
2021
Q2 | $909K | Sell |
63,647
-10,695
| -14% | -$177K | ﹤0.01% | 4750 |
|
|
2021
Q1 | $1.76M | Buy |
+74,342
| New | +$1.93M | ﹤0.01% | 3652 |
|
|
2020
Q4 | – | Sell |
-39,865
| Closed | -$276 | – | 5374 |
|
|
2020
Q3 | $276 | Sell |
39,865
-128,476
| -76% | -$1.28M | ﹤0.01% | 3887 |
|
|
2020
Q2 | $2.07M | Sell |
168,341
-154,658
| -48% | -$873K | ﹤0.01% | 2514 |
|
|
2020
Q1 | $930K | Buy |
322,999
+13,660
| +4% | +$68.4K | ﹤0.01% | 2515 |
|
|
2019
Q4 | $1.17M | Sell |
309,339
-109,280
| -26% | -$186K | ﹤0.01% | 2934 |
|
|
2019
Q3 | $510K | Sell |
418,619
-417,140
| -50% | -$518K | ﹤0.01% | 3245 |
|
|
2019
Q2 | $852K | Buy |
835,759
+798,711
| +2,156% | +$921K | ﹤0.01% | 2896 |
|
|
2019
Q1 | $59K | Sell |
37,048
-81,018
| -69% | -$102K | ﹤0.01% | 3891 |
|
|
2018
Q4 | $137K | Sell |
118,066
-7,375
| -6% | -$16.9K | ﹤0.01% | 3497 |
|
|
2018
Q3 | $464K | Sell |
125,441
-74,989
| -37% | -$237K | ﹤0.01% | 3287 |
|
|
2018
Q2 | $613K | Buy |
200,430
+43,686
| +28% | +$162K | ﹤0.01% | 3070 |
|
|
2018
Q1 | $610K | Buy |
156,744
+125,544
| +402% | +$550K | ﹤0.01% | 2940 |
|
|
2017
Q4 | $140K | Sell |
31,200
-4,857
| -13% | -$23K | ﹤0.01% | 3599 |
|
|
2017
Q3 | $198K | Sell |
36,057
-1,883
| -5% | -$11.6K | ﹤0.01% | 3250 |
|
|
2017
Q2 | $288K | Sell |
37,940
-1,176
| -3% | -$5.08K | ﹤0.01% | 3056 |
|
|
2017
Q1 | $139K | Sell |
39,116
-106,291
| -73% | -$525K | ﹤0.01% | 3290 |
|
|
2016
Q4 | $832K | Buy |
+145,407
| New | +$970K | ﹤0.01% | 2352 |
|
|
2016
Q2 | – | Sell |
-23,685
| Closed | -$195K | – | 3343 |
|
|
2016
Q1 | $195K | Buy |
+23,685
| New | +$223K | ﹤0.01% | 2961 |
|
Other funds holding IBRX
VPM
VCM
HF
WP
Millennium Management's IBRX Position: Q1 2026 in Review
Millennium Management increased its ImmunityBio (IBRX) stake by 1,099% in Q1 2026, buying an estimated $8.91M and bringing the position to 1,420,244 shares worth $10.9M. The position accounts for ﹤0.01% of the portfolio, ranked #2094.
Millennium Management first reported a position in IBRX in Q1 2016 and has held it in 36 quarters since. 386 funds tracked by Wall St. Rank hold IBRX as of Q1 2026.
- Millennium Management held 1,420,244 shares of ImmunityBio worth $10.9M as of Q1 2026.
- Millennium Management bought 1,301,816 ImmunityBio shares in Q1 2026, an estimated $8.91M.
- ImmunityBio made up ﹤0.01% of Millennium Management's portfolio in Q1 2026, its #2094 holding.
- Millennium Management first reported a position in ImmunityBio in Q1 2016 and has held it in 36 quarters since.
- 386 funds tracked by Wall St. Rank held ImmunityBio as of Q1 2026.
Based on Millennium Management's 13F filing for Q1 2026, filed 15 May 2026.